Antisense oligonucleotides: From design to therapeutic application

被引:327
作者
Chan, JHP
Lim, SH
Wong, WSF
机构
[1] Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Singapore 117597, Singapore
[2] Natl Univ Singapore, Immunol Program, Singapore 117597, Singapore
关键词
antisense oligonucleotide design; cell-penetrating peptide; dendrimer; gapmer antisense oligonucleotide; liposome; locked nucleic acid; peptide nucleic acid; phosphoroamidate morpholino oligomer; phosphorothioate; RNase H;
D O I
10.1111/j.1440-1681.2006.04403.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. An antisense oligonucleotide (ASO) is a short strand of deoxyribonucleotide analogue that hybridizes with the complementary mRNA in a sequence-specific manner via Watson-Crick base pairing. Formation of the ASO-mRNA heteroduplex either triggers RNase H activity, leading to mRNA degradation, induces translational arrest by steric hindrance of ribosomal activity, interferes with mRNA maturation by inhibiting splicing or destabilizes pre-mRNA in the nucleus, resulting in downregulation of target protein expression. 2. The ASO is not only a useful experimental tool in protein target identification and validation, but also a highly selective therapeutic strategy for diseases with dysregulated protein expression. 3. In the present review, we discuss various theoretical approaches to rational design of ASO, chemical modifications of ASO, ASO delivery systems and ASO-related toxicology. Finally, we survey ASO drugs in various current clinical studies.
引用
收藏
页码:533 / 540
页数:8
相关论文
共 61 条
  • [1] Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal-transduction inhibitors
    Altmann, KH
    Fabbro, D
    Dean, NM
    Geiger, T
    Monia, BP
    Muller, M
    Nicklin, P
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1996, 24 (03) : 630 - 637
  • [2] Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers
    Amantana, A
    Iversen, PL
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (05) : 550 - 555
  • [3] Secondary structure prediction of interacting RNA molecules
    Andronescu, M
    Zhang, ZC
    Condon, A
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2005, 345 (05) : 987 - 1001
  • [4] Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
    Badros, A
    Goloubeva, O
    Rapoport, AP
    Ratterree, B
    Gahres, N
    Meisenberg, B
    Takebe, N
    Heyman, M
    Zwiebel, J
    Streicher, H
    Gocke, CD
    Tomic, D
    Flaws, JA
    Zhang, B
    Fenton, RG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4089 - 4099
  • [5] Belfort R, 2002, AM J OPHTHALMOL, V133, P467
  • [6] Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to trastuzumab
    Biroccio, A
    D'Angelo, C
    Jansen, B
    Cleave, ME
    Zupi, G
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2005, 204 (02) : 463 - 469
  • [7] TargetFinder: a software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA
    Bo, XC
    Wang, SQ
    [J]. BIOINFORMATICS, 2005, 21 (08) : 1401 - 1402
  • [8] Computational antisense oligo prediction with a neural network model
    Chalk, AM
    Sonnhammer, ELL
    [J]. BIOINFORMATICS, 2002, 18 (12) : 1567 - 1575
  • [9] A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
    Chi, KN
    Eisenhauer, E
    Fazli, L
    Jones, EC
    Goldenberg, SL
    Powers, J
    Tu, DS
    Gleave, ME
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) : 1287 - 1296
  • [10] Antisense DNAs as multisite genomic modulators identified by DNA microarray
    Cho, YS
    Kim, MK
    Cheadle, C
    Neary, C
    Becker, KG
    Cho-Chung, YS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) : 9819 - 9823